Corporate Snapshot
DermWorx, Inc. ("DermWorx" or "the Company") is a closely held specialty pharmaceutical company utilizing unique and novel drug delivery systems to develop more effective versions of currently available dermatology products and cosmeceuticals. The Company has in-licensed a unique and novel Novasome® Microvesicle Drug Delivery System, which significantly increases a compound's aqueous solubility (moisture), penetrability, and stability. DermWorx has also internally developed a unique delivery system, termed Small Molecule Solubilization System™ (SMSS™), which enables molecules of selected actives to rapidly penetrate the skin, thereby increasing the onset of action and therapeutic effect. DermWorx's pipeline focuses on creating products for use in some of the fastest growing and largest sectors of the dermatology market, including non-invasive and invasive surgical procedures, acne, onychomycosis, psoriasis, seborrheic dermatitis, anti-aging cosmeceuticals, and tinea versicolor. The pipeline reflects the armamentarium used in today's dermatology practices. DermWorx expects to have its first three products—LidoWorx™ (a topical anesthetic), CerumWorx™ (an antioxidant serum containing Vitamin C), and AcneWorx™ (an adult acne/dry skin formulation)—market-ready shortly after becoming fully operational. DermWorx is headquartered in Hollywood, Florida.
* The Corporate Snapshot was last updated on May 18, 2007.
Latest Research
Executive
Informational
Overview
2007-05-18
Click to View